spiz  
cens
ic Publicaciones de miembros de FEETEG

En esta sección les ofrecemos una selección de publicaciones realizadas por miembros de FEETEG, así como los enlaces a dichas publicaciones.

 
Medrano-Engay B, Irun P, Gervas-Arruga J, Andrade-Campos M, Andreu V, Alfonso P, Pocovi M, Giraldo P. Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2014

[ Acceso a la publicación >>> ]

Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis . 2014

[ Acceso a la publicación >>> ]

Alfonso P, Andreu V, Pino-Angeles A, Moya-García AA, García-Moreno MI, Rodríguez-Rey JC, Sánchez-Jiménez F, Pocoví M, Ortiz Mellet C, García Fernández JM, Giraldo P. Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease . Chembiochem. 2013;27(14):943-9

[ Acceso a la publicación >>> ]

Alfonso P, Navascués J, Navarro S, Medina P, Bolado-Carrancio A, Andreu V, Irún P, Rodríguez-Rey JC, Pocoví M, España F, Giraldo P. Characterization of Variants in the Glucosylceramide Synthase Gene and their Association with Type 1 Gaucher Disease Severity. Hum Mutat. 2013;34:1396-403

[ Acceso a la publicación >>> ]

Barrett MJ, Giraldo P, Capablo JL, Alfonso P, Irun P, Garcia-Rodriguez B,Pocovi M, Pastores GM. Greater risk of parkinsonism associated with non-N370S GBA1 mutations . J Inherit Metab Dis. 2013;36:575-80

[ Acceso a la publicación >>> ]

Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88:179-84

[ Acceso a la publicación >>> ]

Irún P, Alfonso P, Aznarez S, Giraldo P, Pocovi M. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem. 2013;46(18):1804-7

[ Acceso a la publicación >>> ]

Irun P, Mallén M, Dominguez C, Rodriguez-Sureda V, Alvarez-Sala L, Arslan N, Bermejo N, Guerrero C, Perez de Soto I, Villalón L, Giraldo P, Pocovi M. Identification of seven novel SMPD1 mutations causing Niemann-Pick disease types A and B. Clin Genet. 2013;84:356-61

[ Acceso a la publicación >>> ]

Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013;51:116-24

[ Acceso a la publicación >>> ]

Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013;88:172-8

[ Acceso a la publicación >>> ]

[ Mostrar publicaciones anteriores a 2013 ]

 

FEETEG - Aviso legal